companydata.dkcompanydata.dk

Perfusion Tech ApS: Financial statements 2024

CVR: 38238213

Source: annual report 2024, Danish Business Authority

01/01/202431/12/2024

Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -9,021,930 and a net result of DKK -14,469,520 compared with DKK -9,544,785 the year before. Equity in the 2024 report amounted to DKK 2,114,073. The solvency ratio was 37.8%. The company had 11 employees in the financial year.

Gross Profit
DKK -9,021,930
Profit/Loss
DKK -14,469,520
Equity
DKK 2,114,073
Total Assets
DKK 5,585,408
Employees
11

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--9 mio.-14.5 mio.2.1 mio.11
2023--5.4 mio.-9.5 mio.2.9 mio.8
2022--4.2 mio.-6.6 mio.1.2 mio.7
2021--1.1 mio.-2.1 mio.-3.9 mio.4
2020--1.1 mio.-1.5 mio.-1.8 mio.3

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Perfusion Tech ApS: The 2023 annual report is outMar 25, 2024

Perfusion Tech ApS has published its annual report for 2023. Gross profit came to DKK -5,414,376, and the net result was DKK -9,544,785.

Mads Aagaard Linde Madsen joins the board of Perfusion Tech ApSMar 13, 2024

As of March 13, 2024, Mads Aagaard Linde Madsen has joined the board of directors of Perfusion Tech ApS.

Morten Asp Vonsild Lund leaves the board of Perfusion Tech ApSMar 13, 2024

As of March 13, 2024, Morten Asp Vonsild Lund has left the board of directors of Perfusion Tech ApS.

About Perfusion Tech ApS

Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The board consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. According to the 2025 annual report, the company had an average of 11 employees. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity in the 2025 report amounted to DKK -9,640,655.

Source: annual report 2025, Danish Business Authority